Literature DB >> 22943572

Disruption of raphé serotonergic neural projections to the cortex: a potential pathway contributing to remote loss of brainstem neurons following neonatal hypoxic-ischemic brain injury.

Hanna E Reinebrant1, Julie A Wixey, Kathryn M Buller.   

Abstract

Neuronal injury is a key feature of neonatal hypoxic-ischemic (HI) brain injury. However, the mechanisms underpinning neuronal losses, such as in the brainstem, are poorly understood. One possibility is that disrupted neural connections between the cortex and brainstem may compromise the survival of neuronal cell bodies in the brainstem. We investigated whether brainstem raphé serotonergic neurons that project to the cortex are lost after HI. We also tested if neuroinflammation has a role in disrupting brainstem raphé projections. Postnatal day 3 (P3) rats underwent unilateral carotid artery ligation followed by hypoxia (6% oxygen for 30 min). A retrograde tracer, choleratoxin b, was deposited in the motor cortex on P38. On P45 we found that retrogradely labelled neurons in the dorsal raphé dorsal, ventrolateral, interfascicular, caudal and ventral nuclei were lost after P3 HI. All retrogradely labelled neurons in the raphé nuclei were serotonergic. Numbers of retrogradely labelled neurons were also reduced in the ventromedial thalamus and basolateral amygdala. Minocycline treatment (45 mg/kg 2 h post-HI, 22.5 mg/kg daily P4-P9) attenuated losses of retrogradely labelled neurons in the dorsal raphé ventrolateral, interfascicular and ventral raphé nuclei, and the ventromedial thalamus. These results indicate that raphé neurons projecting to the cortex constitute a population of serotonergic neurons that are lost after P3 HI. Furthermore, neuroinflammation has a role in the disruption of raphé and thalamic neural projections. Future studies investigating the cellular mechanisms of axonal degeneration may reveal new targets for interventions to prevent neuronal losses after neonatal HI.
© 2012 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943572     DOI: 10.1111/j.1460-9568.2012.08276.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  6 in total

1.  Long-Term Neuropathological Changes Associated with Cerebral Palsy in a Nonhuman Primate Model of Hypoxic-Ischemic Encephalopathy.

Authors:  Ryan M McAdams; Bobbi Fleiss; Christopher Traudt; Leslie Schwendimann; Jessica M Snyder; Robin L Haynes; Niranjana Natarajan; Pierre Gressens; Sandra E Juul
Journal:  Dev Neurosci       Date:  2017-05-10       Impact factor: 2.984

2.  Minocycline causes widespread cell death and increases microglial labeling in the neonatal mouse brain.

Authors:  J Alex Strahan; William H Walker; Taylor R Montgomery; Nancy G Forger
Journal:  Dev Neurobiol       Date:  2016-10-14       Impact factor: 3.964

3.  Disruption to the 5-HT7 Receptor Following Hypoxia-Ischemia in the Immature Rodent Brain.

Authors:  Julie A Wixey; Hanna E Reinebrant; Kirat K Chand; Kathryn M Buller
Journal:  Neurochem Res       Date:  2018-01-22       Impact factor: 3.996

4.  Characterization of Gene Expression in the Rat Brainstem After Neonatal Hypoxic-Ischemic Injury and Antioxidant Treatment.

Authors:  M Revuelta; O Arteaga; A Alvarez; A Martinez-Ibargüen; E Hilario
Journal:  Mol Neurobiol       Date:  2016-01-25       Impact factor: 5.590

5.  Hypoxia-ischemia in the immature rodent brain impairs serotonergic neuronal function in certain dorsal raphé nuclei.

Authors:  Hanna E Reinebrant; Julie A Wixey; Kathryn M Buller
Journal:  Neural Regen Res       Date:  2020-03       Impact factor: 5.135

6.  Chronic oral administration of minocycline to sheep with ovine CLN6 neuronal ceroid lipofuscinosis maintains pharmacological concentrations in the brain but does not suppress neuroinflammation or disease progression.

Authors:  Graham W Kay; David N Palmer
Journal:  J Neuroinflammation       Date:  2013-07-30       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.